Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Berko ER, Witek GM, Matkar S, Petrova ZO, Wu MA, Smith CM, Daniels A, Kalna J, Kennedy A, Gostuski I, Casey C, Krytska K, Gerelus M, Pavlick D, Ghazarian S, Park JR, Marachelian A, Maris JM, Goldsmith KC, Radhakrishnan R, Lemmon MA, Mossé YP.
Berko ER, et al. Among authors: park jr.
Nat Commun. 2023 May 5;14(1):2601. doi: 10.1038/s41467-023-38195-0.
Nat Commun. 2023.
PMID: 37147298
Free PMC article.